To investigate if administration of methylprednisone before surgery could decrease the incidence of urosepsis postoperative in patients with high risks undergoing percutaneous nephrolithotomy

The effectiveness of methylprednisone to pevent urosepsis after percutaneous nephrolithotomy in patients with high risk

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16524336

Enrollment

100

Registered

2018-05-21

Start date

2018-06-01

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urosepsis after percutaneous nephrolithotomy Infections and Infestations Urosepsis

Interventions

Current interventions as of 24/09/2018: After induction of general anesthesia, participants are allocated to one of two groups using stratified block randomization, with the stratified

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Scheduled to undergo elective percutaneous nephrolithotomy 2. History of urinary tract infection 3. Once urine culture positive 4. Count of white blood cell in urine = 500/ul 5. Aged over 17 years

Exclusion criteria

Exclusion criteria: 1. Allergic to methylprednisone 2. Use corticosteroids within one month before the operation 3. Use immunodepressant 4. Fasting blood glucose more than 11 mmol/L 5. Active digestive tract ulcer 6. Emergency surgery 7. Pregnant women

Design outcomes

Primary

Measure	Time frame
Incidence of urosepsis is recorded postoperatively by the investigator	—

Secondary

Measure	Time frame
Incidence of systemic inflammatory response syndrome (SIRS) and uroseptic shock is recorded postoperatively by the investigator	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026